Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A Rare Neurological Complication of Ranolazine

View through CrossRef
Myoclonus is not a known side effect of ranolazine. We report a case of myoclonus in a 72-year-old female who underwent cardiac catheterization for angina and was started on ranolazine after the procedure. Two days after ranolazine therapy on 1000 mg per day in divided doses, myoclonus developed, which severely impaired her normal activity. Her symptoms resolved 2 days after discontinuation of ranolazine. Ranolazine was resumed after discharge from hospital with recurrent myoclonus after two days of therapy. The causal relationship between ranolazine and myoclonus was suggested by cessation of myoclonus after ranolazine was discontinued.
Title: A Rare Neurological Complication of Ranolazine
Description:
Myoclonus is not a known side effect of ranolazine.
We report a case of myoclonus in a 72-year-old female who underwent cardiac catheterization for angina and was started on ranolazine after the procedure.
Two days after ranolazine therapy on 1000 mg per day in divided doses, myoclonus developed, which severely impaired her normal activity.
Her symptoms resolved 2 days after discontinuation of ranolazine.
Ranolazine was resumed after discharge from hospital with recurrent myoclonus after two days of therapy.
The causal relationship between ranolazine and myoclonus was suggested by cessation of myoclonus after ranolazine was discontinued.

Related Results

Ranolazine-Tacrolimus Interaction
Ranolazine-Tacrolimus Interaction
Objective: To report the case of a kidney allograft recipient on a stable regimen of tacrolimus who exhibited increased tacrolimus concentrations within 24 hour...
COMPARISON OF EFFICACY AND SAFETY OF RANOLAZINE AND IVABRADINE IN CHRONIC ISCHEMIC HEART DISEASE PATIENTS
COMPARISON OF EFFICACY AND SAFETY OF RANOLAZINE AND IVABRADINE IN CHRONIC ISCHEMIC HEART DISEASE PATIENTS
Background:  Ischemic heart disease (IHD) frequently produces persistent angina that may significantly impair quality of life despite standard treatment. There is need for effectiv...
Open‐label trial of ranolazine for the treatment of paramyotonia congenita
Open‐label trial of ranolazine for the treatment of paramyotonia congenita
ABSTRACTIntroductionParamyotonia congenita (PMC) is a nondystrophic myotonic disorder that is believed to be caused by a defect in Nav1.4 sodium channel inactivation. Ranolazine, w...
Ranolazine for Angina in Hypertrophic Cardiomyopathy
Ranolazine for Angina in Hypertrophic Cardiomyopathy
Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL). However, its use is limited mostly to patients with coronary artery disease. However, literature ha...
Neurological Symptoms and Cause of Death Among Young Children in Low- and Middle-Income Countries
Neurological Symptoms and Cause of Death Among Young Children in Low- and Middle-Income Countries
ImportanceThe emergence of acute neurological symptoms in children necessitates immediate intervention. Although low- and middle-income countries (LMICs) bear the highest burden of...
Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8)
Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8)
Long QT eight (LQT8), otherwise known as Timothy syndrome (TS), is a genetic disorder causing hyper‐activation of the L‐type calcium channel Cav 1.2. This calcium load and the resu...
Functional neurological disorders in patients with brain tumours
Functional neurological disorders in patients with brain tumours
Abstract Aims Signs and symptoms that develop in people with brain tumours are often attributed to their tumour. The prevalence ...

Back to Top